[Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms]. / Fagoterapiia posleoperatsionnykh gnoino-vospalite'lnykh oslozhnenii u onkologicheskikh bo'lnykh.

The authors assess the efficacy of phage therapy ofsuppurative and inflammatory complications in oncological patients. A clinical and laboratory analysis has involved 131 patients whose etiotropic therapy consisted of bacteriophages (65 patients) and antibiotics (66). Medicinal phages, manufactured by the Tbilisi Research Institute for Vaccines and Sera, have been administered according to 3 schemes: (1) parallel with antibiotics, (2) after long ineffective antibiotic therapy, (3) phages alone starting from the onset of the purulent complication. The preparations have been prescribed with due consideration for the isolated microflora sensitivity. Incorporation of phages in combined therapy of infectious complications has yielded positive results in 81.5% of cases, whereas antibiotics have proved effective in but 60.6%. The efficacy of phage therapy depends on the type of pyoinflammatory complications (the results are the best in the management of wound infections), the microflora pattern of the purulent foci (phages are the most effective with a corresponding monoinfection), characteristics of the therapeutic phages proper (Pseudomonas aeruginosa phage is characterized by the highest therapeutic activity, as compared to staphylococcal and other phages).

[A complex vaccine in the prevention of staphylococcal, Pseudomonas aeruginosa and Proteus infections in esophageal cancer patients]. / Kompleksnaia vaktsina v profilaktike stafilokokkovoi, sinegnoinoi i proteinoi infektsii u bol'nykh rakom pishchevoda.

An analysis of clinico-immunological data has demonstrated a considerable decline in non-specific and specific defences against such major factors of hospital infection in esophageal cancer patients as staphylococcal, blue pus and Proteus bacilli. Immunization with a complex vaccine including concentrated staphylococcal anatoxin, blue pus and Proteus vaccines was shown to stimulate the said factors of anti-infectious immunity and to be followed by a 4.7-fold decrease in the incidence of postoperative pyo-inflammatory complications. The said vaccine may be recommended for prevention of infectious complications in cancer patients since its administration is followed by a low-level reaction matched by a marked increase in immunologic vigor.